EP0428105A2 - Verwendung von Chinolyl- und Isochinolyloxazol-2-onen zur Herstellung eines Arzneimittels zur Verhinderung der Ansteckungsfähigkeit von mit Glykoproteinen umhüllten Viren - Google Patents

Verwendung von Chinolyl- und Isochinolyloxazol-2-onen zur Herstellung eines Arzneimittels zur Verhinderung der Ansteckungsfähigkeit von mit Glykoproteinen umhüllten Viren Download PDF

Info

Publication number
EP0428105A2
EP0428105A2 EP90121632A EP90121632A EP0428105A2 EP 0428105 A2 EP0428105 A2 EP 0428105A2 EP 90121632 A EP90121632 A EP 90121632A EP 90121632 A EP90121632 A EP 90121632A EP 0428105 A2 EP0428105 A2 EP 0428105A2
Authority
EP
European Patent Office
Prior art keywords
compound
formula
quinolinyl
oxazolone
quinolyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP90121632A
Other languages
English (en)
French (fr)
Other versions
EP0428105B1 (de
EP0428105A3 (en
Inventor
Sai P. Sunkara
Winton D. Jones
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Merrell Dow Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharmaceuticals Inc filed Critical Merrell Dow Pharmaceuticals Inc
Priority to AT90121632T priority Critical patent/ATE100318T1/de
Publication of EP0428105A2 publication Critical patent/EP0428105A2/de
Publication of EP0428105A3 publication Critical patent/EP0428105A3/en
Application granted granted Critical
Publication of EP0428105B1 publication Critical patent/EP0428105B1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Definitions

  • This invention relates to the use of certain quinolyl- and isoquinolyloxazole-2-ones in the treatment and prevention of infections by enveloped virus including retroviral, e.g., HIV, infections.
  • Retroviruses are a class of ribonucleic acid (RNA) viruses that replicate by using reverse transcriptase to form a strand of complementary DNA (cDNA) from which a double stranded,proviral DNA is produced. This proviral DNA is then randomly incorporated into the chromasomal DNA of the host cell making possible viral replication by later translation of the integrated DNA containing the viral genome.
  • RNA ribonucleic acid
  • retroviruses are oncogenic or tumor causing. Indeed the first two human retroviruses discovered, denoted human T-cell leukemia virus I and II or HTLV-I and II, were found to cause rare leukemias in humans after infection of T-lymphocytes. The third such human virus to be discovered, HTLV-III, now referred to as HIV, was found to cause cell death after infection of T-lymphocytes, specifically the CD4+ subpopulation, and has been identified as the causative agent of acquired immune deficiency syndrome (AIDS) and AIDS related complex (ARC).
  • AIDS acquired immune deficiency syndrome
  • ARC AIDS related complex
  • Retroviruses have, in addition to the usual viral capsid, an outer membrane of lipid and glycoprotein, similar to the membrane of ordinary cells. Indeed the lipid of the retroviral membrane is probably derived directly from the membrane of a previously infected host cell, however, the glycoprotein of the viral membrane is unique to the virus itself and is coded for by the viral genome. Infection of a host cell by a retrovirus initially relies on the interaction of various receptors on the host cell surface with the glycoprotein membrane envelope of the virus.
  • the glycoprotein envelope of the retroviruses plays an important role in both the initial interaction of the virion and the host cell and in the later fusion of the viral and host cell membranes.
  • viruses are coated or enveloped by a glycoprotein layer as well.
  • viruses include the herpes simplex viruses (HSV), the influenza viruses, cytomegloviruses (CMG), and others.
  • Applicants have determined that certain quinolyl- and isoquinolyloxazole-2-ones having PKC inhibiting activity are useful in the treatment of various enveloped virus infections including in the treatment of AIDS and ARC resulting from infection by HIV or other retroviruses.
  • the present invention is directed to the use of certain quinolyl- and isoquinolyloxazole-2-ones of the formula wherein R and R1 are each independently selected from the group consisting of hydrogen, C1-C6 alkyl, and phenyl or C1-C3 alkylphenyl wherein the phenyl ring is optionally substituted with one, two or three of the substituents selected from the group consisting of fluorine, chlorine, bromine, C1-C4 alkyl, and C1-C4 alkoxy; and R2 is a 2-, 3-, or 4-quinolyl group or a 1-, 3-, or 4-­isoquinolyl group wherein the quninolyl or isoquinolyl group is optionally substituted with one, two or three of the substituents selected from the group consisting of fluorine, chlorine, bromine, C1-C4 alkyl, C1-C4 alkoxy, nitro, trifluoromethyl, and phenyl optionally substituted with one, two
  • This invention concerns the use of the compounds of Formula I as agents effective in the treatment of infections of enveloped viruses.
  • C1-C3 alkyl mean straight or branched chain alkyl groups having from one to three, from one to four, or from one to six carbon atoms respectively, and include such groups as methyl, ethyl, n -propyl, isopropyl, n -butyl, isobutyl, sec -butyl, tert -­butyl, and the like, as well as vinyl, allyl, propynyl, butenyl, butadienyl, isopropenyl, and the like.
  • C1-C4 alkoxy means alkoxy groups having from one to four carbon atoms, and includes such groups as methoxy, ethoxy, n -­propoxy, isopropoxy, n -butoxy, isobutoxy, sec -butoxy, tert -­butoxy, and the like.
  • R or R1 is "optionally substituted C1-C3 alkylphenyl"
  • the one, two or three substituent(s) can be located at any available position on the phenyl ring.
  • R2 is 2-, 3-, or 4-quinolyl or 1-, 3-, or 4-isoquinolyl
  • the optional substituent(s) can be located at any available position(s) on the quinolyl or isoquinolyl ring.
  • a pharmaceutically acceptable acid addition salt is intended to apply to any non-toxic organic or inorganic acid addition salt of the base compounds.
  • Illustrative inorganic acids which form suitable salts include hydrochloric, hydrobromic, sulfuric, and phosphoric acids and acid metal salts such as sodium monohydrogen orthophosphate and potassium hydrogen sulfate.
  • Illustrative organic acids which form suitable salts include the mono, di, and tricarboxylic acids.
  • Such acids are,for example, acetic, glycolic, lactic, pyruvic, malonic, succinic, glutaric, fumaric, malic, tartaric, citric, ascorbic, maleic, hydroxymaleic, benzoic, hydroxybenzoic, phenylacetic, cinnamic, salicylic, and 2-phenoxybenzoic acids.
  • Other organic acids which form suitable salts are the sulfonic acids such as methane sulfonic acid and 2-hydroxyethane sulfonic acid.
  • the acid salts are prepared by standard techniques such as by dissolving the free base in aqueous or aqueous-alcohol solution or other suitable solvent containing the appropriate acid and isolating by evaporating the solution, or by reacting the free base in an organic solvent in which case the salt separates directly or can be obtained by concentration of the solution.
  • the acid addition salts of the compounds of this invention are crystalline materials which are soluble in water and various hydrophilic organic solvents and which in comparison to their free base forms, demonstrate higher melting points and an increased solubility.
  • isoquinolyl derivatives are also intended. As is true for most classes of therapeutically effective compounds, certain subclasses and certain species which are especially effective are preferred over others. In this instance, those compounds of Formula I wherein R2 is optionally substituted 2-, 3-, or 4-quinolyl are preferred. Also preferred are compounds wherein R is C1-C6 alkyl, as well as compounds wherein R1 is hydrogen. Most preferred are the compounds wherein R2 is an unsubstituted 2-, 3-, or 4-quinolyl group, R is ethyl or propyl and R1 is hydrogen.
  • Reaction Scheme 1 illustrates that the 2-, 3-, or 4-quinolyloxazole-2-ones of Formula I can be prepared by reacting the appropriate and readily available 2-, 3-, or 4-­quinoline carboxaldehyde (II) in tetrahydrofuran (THF) with alkylmagnesium chloride or with optionally substituted phenylalkyl-magnesium chloride (RMgCl] to produce 2-, 3-, or 4-­quinoline alkanol (III), which is in turn oxidized with oxalyl chloride (ClCOCOCl), methyl sulfoxide [(CH3)2SO] and triethylamine (Et3N) in dichloromethane (CH2Cl2) to produce quinolyl-alkanone (IV).
  • the alkanone (IV) can alternately be brominated to compound (VIII a ) and further treated with triethylamine in dimethylformamide (DMF) in the presence of potassium cyanate (KCNO) to form the compounds of Formula I according to procedures well known in the art and illustrated in the examples herein; or compound IV can be converted to oxime (V) by refluxing with hydroxylamine hydrochloride (H2NOH ⁇ HCl) and pyridine in ethanol (EtOH). Compound (V) is then reacted with p-toluenesulfonyl chloride and triethylamine in dichloromethane to produce compound (VI).
  • DMF dimethylformamide
  • KCNO potassium cyanate
  • the amine (VII) is then produced by reacting compound (VI) with sodium ethoxide in ethanol (NaOEt/EtOH), followed by ether and aqueous hydrochloric acid (HCl) extraction.
  • the amine (VII) is further reacted with 1,1′-carbonyldiimidazole at about 0°C to form compound (VIII b ), which is then heated to about 170°C to yield the appropriate 2-, 3-, or 4-quinolyloxazole-2-ones of Formula I.
  • Reaction Scheme 2 illustrates that the 5-, 6-, 7-, or 8-quinolyloxazole-2-ones of Formula I can be prepared in essentially the same manner as described for Reaction Scheme 1.
  • the alkanone starting material (IX) is prepared by metalating 5-, 6-, 7- or 8-bromoquinoline according to a procedure by H. Gilman and T. Suddy set forth in J. Org. Chem. 23 , 1584-9 (1958), and then reacting it with N-alkoxy-N-alkylamides.
  • the 5-, 6-, 7-, or 8-bromoquinoline compounds are prepared by following procedures set forth in "The Chemistry of Heterocyclic Compounds" by Gurnos Jones, as found in Quinolines , Part 1, vol.
  • the formula (IV) and formula (IX) compounds of Reaction Schemes 1 or 2 can also be prepared by reacting the appropriate bromoquinoline with butyl lithium in an appropriate solvent such as THF or diethyl ether at -70°C to 0°C, preferably at -50°C, and then reacting the lithiated compound with wherein R is as described in Formula I. This reaction is further specifically exemplified in Example 8.
  • Compound (XIV) can be prepared by a procedure set forth in Tetrahedron Letters , 22 , 3815 (1981).
  • R1 is C1-C6 alkyl or optionally substituted C1-C3 alkylphenyl are produced by subsequent reaction of the compound of Formula I of either Reaction Scheme 1 or Reaction Scheme 2 with sodium hydride and the appropriate alkyl iodide or phenylalkyl iodide in tetrahydrofuran according to procedures well known in the art.
  • oxazolone derivatives of this invention act as anti-enveloped virus agents can be demonstrated by their ability to inhibit the growth and replication of murine leukemia virus, an oncogenic retrovirus, as determined by an in vitro XC plaque assay.
  • This assay was performed according to the method of Rowe et al . ( Virology , 1970, 42 , 1136-39) as previously described by L. Hsu, et al . ( J. Virological Methods , 1980, 1 , 167-77) and T. L. Bowlin and M. R. Proffitt ( J. Interferon Res. , 1983, 3(1) , 19-31).
  • Mouse SC-1 cells (fibroblast) (105) were seeded into each well of 6-well cluster plates (Costar #3506) in 4 ml Minimum Essential Medium (MEM) with 10% Fetal Calf Serum (FCS). Following an 18 hour incubation period (37°C), Moloney murine leukemia virus (MoLV) was applied at a predetermined titer to give optimal (i.e. countable) numbers of virus plaques. Compounds were added 2 hours prior to addition of the virus. Three days later the culture medium was removed, the SC-1 cell monolayers were exposed to UV irradiation (1800 ergs), and rat XC cells (106) were seeded into each well in 4 ml MEM.
  • MEM Minimum Essential Medium
  • FCS Fetal Calf Serum
  • the ability of the oxazolone derivatives of this invention to act as anti-enveloped virus agents can be demonstrated by their ability to reduce expression of p24 antigen from HIV infected T-lymphocytes.
  • Cells (C8166 T cell line) were pretreated with test compounds at appropriate concentrations for 3 hours prior to virus (RF strain of HIV-1) absorption. Low multiplicity of infection was used and virus absorption period was 1 hour at room temperature. the cells were washed X1 in PBS and resuspended in fresh medium containing the appropriate concentrations of test compound. Cells incubated at 37°C and after 3 days culture fluid was assayed for p24 antigen as a measure of viral replication.
  • the oxazolone derivatives of this invention can be used to treat a number of diseases and conditions known to be caused by enveloped viruses including those diseases and conditions caused by murine leukemia virus, feline leukemia virus, cytomegalovirus (CMV), avian sarcoma virus, herpes simplex virus (HSV), invluenza virus, human immunodeficiency virus (HIV), HTLV-Z, and HTLV-II.
  • CMV murine leukemia virus
  • CMV cytomegalovirus
  • HSV herpes simplex virus
  • HIV human immunodeficiency virus
  • HTLV-Z human immunodeficiency virus
  • HTLV-II HTLV-II
  • the amount of the oxazolone derivative of formula 1 to be administered can vary widely according to the particular dosage unit employed, the period of treatment, the age and sex of the patient treated, the nature and extent of the disorder treated, and the particular oxazolone derivative selected. Moreover the oxazolone derivative can be used in conjunction with other agents known to be useful in the treatment of enveloped virus diseases and agents known to be useful to treat the symptoms of and complications associated with diseases and conditions caused by enveloped viruses.
  • the anti-enveloped virally effective amount of a oxazolone derivative of formula 1 to be administered will generally range from about 15 mg/kg to 500 mg/kg.
  • a unit dosage may contain from 25 to 500 mg of the oxazolone derivative, and can be taken one or more times per day.
  • the oxazolone derivative can be administered with a pharmaceutical carrier using conventional dosage unit forms either orally or parenterally.
  • the preferred route of administration is oral administration.
  • the oxazolone derivative can be formulated into solid or liquid preparations such as capsules, pills, tablets, troches, lozenges, melts, powders, solutions, suspensions, or emulsions.
  • the solid unit dosage forms can be a capsule which can be of the ordinary hard- or soft-shelled gelatin type containing, for example, surfactants, lubricants, and inert fillers such as lactose, sucrose, calcium phosphate, and cornstarch.
  • the compounds of this invention can be tableted with conventional tablet bases such as lactose, sucrose, and cornstarch in combination with binders such as acacia, cornstarch, or gelatin, disintegrating agents intended to assist the break-up and dissolution of the tablet following administration such as potato starch, alginic acid, corn starch, and guar gum, lubricants intended to improve the flow of tablet granulations and to prevent the adhesion of tablet material to the surfaces of the tablet dies and punches, for example, talc, stearic acid, or magnesium, calcium, or zinc stearate, dyes, coloring agents, and flavoring agents intended to enhance the aesthetic qualities of the tablets and make them more acceptable to the patient.
  • conventional tablet bases such as lactose, sucrose, and cornstarch in combination with binders such as acacia, cornstarch, or gelatin
  • disintegrating agents intended to assist the break-up and dissolution of the tablet following administration such as potato starch, alginic acid, corn starch,
  • Suitable excipients for use in oral liquid dosage forms include diluents such as water and alcohols, for example, ethanol, benzyl alcohol, and the polyethylene alcohols, either with or without the addition of a pharmaceutically acceptably surfactant, suspending agent, or emulsifying agent.
  • diluents such as water and alcohols, for example, ethanol, benzyl alcohol, and the polyethylene alcohols, either with or without the addition of a pharmaceutically acceptably surfactant, suspending agent, or emulsifying agent.
  • oxazolone derivatives of this invention may also be administered parenterally, that is, subcutaneously, intravenously, intramuscularly, or interperitoneally, as injectable dosages of the compound in a physiologically acceptable diluent with a pharmaceutical carrier which can be a sterile liquid or mixture of liquids such as water, saline, aqueous dextrose and related sugar solutions, an alcohol such as ethanol, isopropanol, or hexadecyl alcohol, glycols such as propylene glycol or polyethylene glycol, glycerol ketals such as 2,2-dimethyl-1,3-dioxolane-4-methanol, ethers such as poly(ethylene-glycol) 400, an oil, a fatty acid, a fatty acid ester or glyceride, or an acetylated fatty acid glyceride with or without the addition of a pharmaceutically acceptable surfactant such as a soap or a detergent, suspending agent such
  • Suitable fatty acids include oleic acid, stearic acid, and isostearic acid.
  • Suitable fatty acid esters are, for example, ethyl oleate and isopropyl myristate.
  • Suitable soaps include fatty alkali metal, ammonium, and triethanolamine salts and suitable detergents include cationic detergents, for example, dimethyl dialkyl ammonium halides, alkyl pyridinium halides, and alkylamines acetates; anionic detergents, for example, alkyl, aryl, and olefin sulfonates, alkyl, olefin, ether, and monoglyceride sulfates, and sulfosuccinates; nonionic detergents, for example, fatty amine oxides, fatty acid alkanolamides, and polyoxyethylenepolypropylene copolymers; and amphoteric detergents, for example, alkyl-beta-­aminopropionates, and 2-alkylimidazoline quarternary ammonium salts, as well as mixtures.
  • suitable detergents include cationic detergents, for example, dimethyl dialkyl ammonium halides
  • compositions of this invention will typically contain from about 0.5 to about 25% by weight of the oxazolone derivative of formula 1 in solution. Preservatives and buffers may also be used advantageously. In order to minimize or eliminate irritation at the site of injection, such compositions may contain a non-­ionic surfactant having a hydrophile-lipophile balance (HLB) of from about 12 to about 17. The quantity of surfactant in such formulations ranges from about 5 to about 15% by weight.
  • the surfactant can be a single component having the above HLB or can be a mixture of two or more components having the desired HLB.
  • surfactants used in parenteral formulations are the class of polyethylene sorbitan fatty acid esters, for example, sorbitan monooleate and the high molecular weight adducts of ethylene oxide with a hydrophobic base, formed by the condensation of propylene oxide with propylene glycol.
  • polyethylene sorbitan fatty acid esters for example, sorbitan monooleate and the high molecular weight adducts of ethylene oxide with a hydrophobic base, formed by the condensation of propylene oxide with propylene glycol.
  • Triethylamine (35.6 ml) was then added and the mixture was allowed to stir cold for about 1 hour. After the mixture had been allowed to warm to room temperature, it was poured into a flask containing about 600 ml water. The CH2Cl2 layer was separated and the aqueous layer extracted with CH2Cl2 (2 times, 100 ml each). The combined CH2Cl2 layers were washed with saturated sodium chloride and dried over magnesium sulfate. The inorganic matter was filtered off and the solvent evaporated leaving a residue that was flash chromatographed as in Example 1. Evaporation left 9.0 grams of title compound.
  • Example 5 The compound of Example 5 (19.8 grams) was dissolved in about 300 ml water, and the solution filtered by gravity into a 1 liter, 3-necked flask equipped with a mechanical stirrer and a thermometer. The solution was cooled to 0°C with stirring in an ice/methanol bath, and 29.87 grams (0.185 M) 1,1′-­carbonyldiimidazole was added over a 5 minute period. The mixture was allowed to stir cold for about 15 minutes. The resulting precipitate was taken up in about 500 ml ethyl acetate and separated from the water. The solution was washed with saturated sodium chloride and dried over magnesium sulfate, and the inorganic matter filtered off using diatomaceous earth under vacuum. The solvent was evaporated leaving the title compound.
  • Example 6 The compound of Example 6 (12 grams) was heated under vacuum to 170°C for about 30 minutes, allowed to cool to room temperature and washed with water. The water was decanted and the residue was treated with CH2Cl2 (20 ml). The CH2Cl2 was evaporated leaving 7.8 grams of residue. The product was purified by means of flash chromatography on silica, eluting with ethyl acetate. The solvent was evaporated and the residue dissolved in 48 ml hot 50% ethanol, filtered and allowed to cool to room temperature. The precipitate was collected by vacuum filtration and dried in vacuo at 78°C, leaving 1.97 grams (21%) title compound. M.p. 188-190°C dec.; analysis calced. for C15H14N2O2: C, 70.85; H, 5.55; N, 11.02; analysis found: C, 71.10; H, 5.73; N, 10.76.
  • n-butyl lithium (0.0025 M, 0.021 ml) was added to 150 ml diethylether. Then 4.16 grams 3-bromoquinoline in 2 ml THF was added dropwise while stirring and maintaining the temperature at -60°C to -55°C. The solution was stirred for 30 minutes, and 2.3 grams N-methyl-N-methoxybutyramide were then added dropwise at -50°C and the solution was stirred an additional 30 minutes. The solution was then allowed to warm to 0°C and stirred for one hour.
  • EXAMPLE 9 A tablet is prepared from 4-Methyl-5-(3-quinolinyl)-1-(3H)-oxazolone 250 mg Starch 40 mg Talc 10 mg Magnesium 10 mg EXAMPLE 10 A capsule is prepared from 4-phenyl-5-(2-quinolinyl)-1-(3H)-oxazolone 400 mg Talc 40 mg Sodium Carboxymethy celulose 40 mg Starch 120 mg
  • compositions which are comprised of an inert carrier and an effective amount of a compound of Formula I, or a salt thereof.
  • An inert carrier is any material which does not interreact with the compound to be carried and which lends support, means of conveyance bulk, traceable material, and the like to the compound to be carried.
  • An effective amount of compound is that amount which produces a result or exerts an influence on the particular procedure being performed.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EP90121632A 1989-11-13 1990-11-12 Verwendung von Chinolyl- und Isochinolyloxazol-2-onen zur Herstellung eines Arzneimittels zur Verhinderung der Ansteckungsfähigkeit von mit Glykoproteinen umhüllten Viren Expired - Lifetime EP0428105B1 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AT90121632T ATE100318T1 (de) 1989-11-13 1990-11-12 Verwendung von chinolyl- und isochinolyloxazol-2- onen zur herstellung eines arzneimittels zur verhinderung der ansteckungsfaehigkeit von mit glykoproteinen umhuellten viren.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43531889A 1989-11-13 1989-11-13
US435318 1989-11-13

Publications (3)

Publication Number Publication Date
EP0428105A2 true EP0428105A2 (de) 1991-05-22
EP0428105A3 EP0428105A3 (en) 1991-12-11
EP0428105B1 EP0428105B1 (de) 1994-01-19

Family

ID=23727911

Family Applications (1)

Application Number Title Priority Date Filing Date
EP90121632A Expired - Lifetime EP0428105B1 (de) 1989-11-13 1990-11-12 Verwendung von Chinolyl- und Isochinolyloxazol-2-onen zur Herstellung eines Arzneimittels zur Verhinderung der Ansteckungsfähigkeit von mit Glykoproteinen umhüllten Viren

Country Status (11)

Country Link
EP (1) EP0428105B1 (de)
JP (1) JP2927930B2 (de)
KR (1) KR0162639B1 (de)
AT (1) ATE100318T1 (de)
AU (1) AU630249B2 (de)
DE (1) DE69006187T2 (de)
DK (1) DK0428105T3 (de)
ES (1) ES2062266T3 (de)
IE (1) IE63851B1 (de)
PH (1) PH27309A (de)
ZA (1) ZA908933B (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998008509A1 (en) * 1996-08-30 1998-03-05 Eli Lilly And Company Use of pkc inhibitors for the manufacture of a medicament for the treatment of aids

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0365863A2 (de) * 1988-10-24 1990-05-02 Merrell Dow Pharmaceuticals Inc. Quinolyloxazol-2-one, nützlich als Proteinkinase-C-Inhibitoren

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0365863A2 (de) * 1988-10-24 1990-05-02 Merrell Dow Pharmaceuticals Inc. Quinolyloxazol-2-one, nützlich als Proteinkinase-C-Inhibitoren

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Fed. Am. Soc. Exp. Biol. 73rd Ann. Meeting, 19-23 March 1989, vol. 3, p. 1, abstract no. A230, H.C. Cheng et al. *
NATURE, vol. 333, 1988, pages 278-280; A.P. FIELDS et al.: "Human immunodeficiency virus induces phosphorylation of its cell surface receptor" *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998008509A1 (en) * 1996-08-30 1998-03-05 Eli Lilly And Company Use of pkc inhibitors for the manufacture of a medicament for the treatment of aids
EP0830860A1 (de) * 1996-08-30 1998-03-25 Eli Lilly And Company Verwendung von PKC-Hemmern zur Herstellung eines Arzneimittels zur Behandlung von AIDS
US6107327A (en) * 1996-08-30 2000-08-22 Eli Lilly And Company Therapeutic treatment for HIV infection

Also Published As

Publication number Publication date
JP2927930B2 (ja) 1999-07-28
DE69006187D1 (de) 1994-03-03
AU6592990A (en) 1991-05-16
KR910009260A (ko) 1991-06-28
DK0428105T3 (da) 1994-02-28
KR0162639B1 (ko) 1998-12-01
IE63851B1 (en) 1995-06-14
DE69006187T2 (de) 1994-05-05
IE904079A1 (en) 1991-05-22
PH27309A (en) 1993-05-28
AU630249B2 (en) 1992-10-22
ATE100318T1 (de) 1994-02-15
ES2062266T3 (es) 1994-12-16
EP0428105B1 (de) 1994-01-19
JPH03173886A (ja) 1991-07-29
EP0428105A3 (en) 1991-12-11
ZA908933B (en) 1991-08-28

Similar Documents

Publication Publication Date Title
RU2245881C2 (ru) Дигидропиримидины, промежуточные продукты и лекарственное средство
JP2022518456A (ja) 置換多環式カルボン酸、その類似体、およびそれらの使用法
SK137899A3 (en) 4,4-disubstituted-3,4-dihydro-2(1h)-quinazolinones useful as hiv reverse transcriptase inhibitors
JP2002512233A (ja) 薬剤としてのジヒドロピリミジン類の使用及び新規な物質
EP0309952B1 (de) Antiretroviraler Castanosperminester
EP0365863B1 (de) Quinolyloxazol-2-one, nützlich als Proteinkinase-C-Inhibitoren
JP2720169B2 (ja) 抗レトロウイルス活性をもつ糖タンパク処理抑制剤
EP2748150B1 (de) Hiv-replikationshemmer
US5061715A (en) Prevention of glycoprotein enveloped virus infectivity by quinolyl- and isoquinolyloxazole-2-zones
EP0345751A1 (de) Antiretrovirale difluorierte Nucleoside
CA2057821A1 (en) Anti-herpes castanospermine esters
EP0428105B1 (de) Verwendung von Chinolyl- und Isochinolyloxazol-2-onen zur Herstellung eines Arzneimittels zur Verhinderung der Ansteckungsfähigkeit von mit Glykoproteinen umhüllten Viren
JPH09512548A (ja) レトロウイルス感染、特にｈｉｖ感染の治療のためのメタノール誘導体
US5063238A (en) Prevention of glycoprotein enveloped virus infectivity by pyridinyloxazole-2-ones
JPH06505017A (ja) 三環式イソインドリノンの抗ウイルス医薬としての使用、ならびに新規な光学活性イソインドリノン
EP0428103A2 (de) Verhinderung der Ansteckungsfähigkeit von mit Glykoproteinen umhüllten Viren durch Pyridyloxazol-2-one
EP0586632A1 (de) Benzodiazepinonen und diese enthaltende Heilmittel
NL8004003A (nl) Chinolinederivaten en farmaceutische preparaten die een dergelijke verbinding bevatten, alsmede werkwijze voor het bereiden van deze verbindingen.
EP0579695A1 (de) Reissert Verbindungen als anti-HIV-Wirkstoffe
US20090048310A1 (en) Agent for prevention/treatment of disease caused by acyclovir-resistant herpesvirus
JPH03170477A (ja) プロテインキナーゼｃ阻害剤として有用なピリジニルオキサゾール―２―オン類
JPH02311479A (ja) キノリン誘導体
NZ622558B2 (en) Hiv replication inhibitors

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19901228

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

17Q First examination report despatched

Effective date: 19921006

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

REF Corresponds to:

Ref document number: 100318

Country of ref document: AT

Date of ref document: 19940215

Kind code of ref document: T

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

REF Corresponds to:

Ref document number: 69006187

Country of ref document: DE

Date of ref document: 19940303

ET Fr: translation filed
ITF It: translation for a ep patent filed
REG Reference to a national code

Ref country code: GR

Ref legal event code: FG4A

Free format text: 3011531

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2062266

Country of ref document: ES

Kind code of ref document: T3

26N No opposition filed
EAL Se: european patent in force in sweden

Ref document number: 90121632.5

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DK

Payment date: 19990913

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 19990921

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 19991004

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 19991005

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 19991013

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 19991027

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 19991103

Year of fee payment: 10

Ref country code: FR

Payment date: 19991103

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 19991116

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 19991125

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 19991214

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 19991220

Year of fee payment: 10

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20001112

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20001112

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20001112

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20001112

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20001113

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: THE PATENT HAS BEEN ANNULLED BY A DECISION OF A NATIONAL AUTHORITY

Effective date: 20001129

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20001130

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20001130

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20001130

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20001130

BERE Be: lapsed

Owner name: MERRELL DOW PHARMACEUTICALS INC.

Effective date: 20001130

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20010601

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20001112

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

EUG Se: european patent has lapsed

Ref document number: 90121632.5

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20010731

NLV4 Nl: lapsed or anulled due to non-payment of the annual fee

Effective date: 20010601

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20010801

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20011214

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED.

Effective date: 20051112